FDA Approves Eli Lilly's and Boehringer Ingelheim Pharmaceuticals' Triple-Combination Diabetes Drug Trijardy XR
On Monday, the Food and Drug Administration approved Trijardy XR, a combination treatment that contains three drugs already approved for type 2 diabetes: Jardiance, Tradjenta, and the generic drug metformin.
Eli Lilly (NYSE: LLY) and its partner, Germany-based Boehringer Ingelheim Pharmaceuticals, will market the drug, as they do Jardiance and Tradjenta. The companies formed a strategic alliance in 2011 that brought their diabetes pipelines together.
Boehringer Ingelheim arguably brought more to the deal -- it owned both Jardiance and Tradjenta -- while Eli Lilly initially made an upfront payment to its new ally to even out the alliance.
Source Fool.com
